Related Experiment Video
Updated: Jul 13, 2026
08:17
Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
Published on: September 27, 2018
Sacral nerve stimulation for fecal disorders: evolution, current status, and future directions
1Chirurgische Klinik der Universität Erlangen, Erlangen, Germany. Klaus.Matzel@chir.imed.uni-erlangen.de
Acta Neurochirurgica. Supplement
|August 19, 2007
Summary
Sacral nerve stimulation (SNS) improves fecal incontinence and quality of life by stimulating the anorectal continence organ. This therapy is effective across various causes, with a predictive test guiding permanent implantation.
Area of Science:
- Neuroscience
- Gastroenterology
- Urology
Background:
- Sacral nerve stimulation (SNS) has been used since 1994 to treat fecal incontinence.
- Its application has expanded, becoming a valuable therapeutic option.
- Patient selection evolved from conceptual to pragmatic trial-and-error, with a predictive temporary test phase.
Purpose of the Study:
- To evaluate the effectiveness of sacral nerve stimulation for fecal incontinence.
- To assess the impact of SNS on patients' quality of life.
- To explore the mechanism of action and potential new applications of SNS.
Main Methods:
- Temporary test stimulation to predict clinical benefit.
- Implantation of a neurostimulation device for chronic stimulation.
- Clinical trials (single and multicentre) across diverse etiologies.
Main Results:
- Permanent SNS improves or restores continence.
- SNS significantly enhances patients' quality of life.
- Effectiveness is demonstrated across a wide range of fecal incontinence causes.
Conclusions:
- Sacral nerve stimulation is an effective treatment for fecal incontinence.
- The therapy offers substantial improvements in quality of life.
- Further research is needed to fully understand its mechanism and expand applications.
Related Concept Videos
01:20Gastrointestinal Motility Disorders
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...